FDA Brief

Warning letters Drugs

FDA warning letter to

DDI Multinacional S.A. de C.V.

High riskIssued Jun 27, 2022Posted Jul 12, 2022Center for Drug Evaluation and Research | CDER

DDI Multinacional hand sanitizers labeled 70% ethanol contained up to 60% methanol, leading to adulteration and import alert.

What happened

FDA tested batches of EARTHS AMENITIES Hand Sanitizer and AGAVESPA skincare HAND SANITIZER that were detained and refused admission at the U.S. border. The labels said the products contained 70% ethanol, but FDA found EARTHS had about 12% ethanol and 60% methanol and AGAVESPA had about 33% ethanol and 35% methanol. FDA said the substitution made the products adulterated (containing an illegal substitute), showed quality assurance was not working under CGMP (current good manufacturing practice), and also made them unapproved and misbranded drugs.

What FDA found

  1. The products' labeled active ingredient, ethanol, was replaced wholly or in part with methanol, making them adulterated.

    FD&C Act section 501(d)(2), 21 U.S.C. 351(d)(2)
  2. The methanol substitution shows the firm's quality assurance was not working under CGMP, making the products adulterated.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  3. The hand sanitizers are unapproved new drugs because they lack FDA approval and do not meet the conditions for selling nonprescription drugs without approval.

    FD&C Act sections 505(a), 301(d); 21 U.S.C. 355(a), 331(d)
  4. The products are misbranded because they are dangerous to health when used as labeled.

    FD&C Act section 502(j), 21 U.S.C. 352(j)
  5. The labels are false or misleading because they claim 70% ethanol and do not disclose methanol.

    FD&C Act section 502(a), 21 U.S.C. 352(a)
  6. The labels do not list methanol as an ingredient.

    FD&C Act section 502(e)(1)(A), 21 U.S.C. 352(e)(1)(A)

What FDA wants

FDA asks DDI to investigate the methanol substitution, list all raw materials and suppliers, reconcile all U.S.-shipped batches with complete batch records, and provide a lab remediation plan, responding in writing within 15 working days. FDA also recommends a qualified CGMP consultant and a Regulatory Meeting if the firm wants to make U.S. drugs in the future.

Who should pay attention

  • brands that buy finished hand sanitizer from contract manufacturers
  • U.S. importers and distributors of consumer antiseptics
  • retailers and buyers of EARTHS AMENITIES or AGAVESPA products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. World Perfumes Inc.

    World Perfumes failed to test drug ingredients for toxic contaminants and had inadequate water, FDA says.

    High risk
  2. RNA Bio/Pharma, Incorporated

    FDA found RNA Bio/Pharma failed to test homeopathic oral liquid drugs for dangerous contaminants and did not validate its water system.

    High risk
  3. Kabana Skin Care LLC

    Kabana Skin Care failed to test OTC drug ingredients and finished products, prompting a recall and halt of U.S. drug manufacturing.

    High risk
  4. Ningbo Riway Industrial Co., Ltd.

    Ningbo Riway Industrial, an OTC drug maker in China, was cited for manufacturing-practice failures and unapproved antiseptic wipes.

    High risk